Press Releases

Promore Pharma’s AGM related Documents Published

Interim report January – March 2023

Promore Pharma’s Annual Report 2022

Promore Pharma AB changes the AGM date to June 27

Invitation to a presentation of the results from Promore Pharma’s clinical trial PHSU05

Promore Pharma reports outcome from clinical Phase II study with ensereptide

Year-end report, 2022

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Fourth Quarter 2022

Promore Pharma reaches the Clean File milestone in its phase II clinical trial with ensereptide

Interim report January – September 2022

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2022

Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma

Promore Pharma provides an update on the Phase II clinical trial with ensereptide

Promore Pharma Interim report January – June 2022

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022

Promore Pharma granted EU patent regarding treatment of chronic wounds

The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide

Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022

Promore Pharma — interim report January-March 2022

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022

Promore Pharma’s Annual Report 2021 and AGM related Documents Published

NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)

Promore Pharma has reached recruitment goal in clinical trial of ensereptide

Interim report January – December 2021

First patient recruited to Promore Pharma’s clinical trial regarding scarring according to plan

Invitation to Conference Call regarding Promore Pharma’s Year-end Report 2021

Promore Pharma deregisters warrants

Promore Pharma granted US patent regarding treatment of chronic wounds

Interim report January – September 2021

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2021

Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma

Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention

Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers

Promore Pharma receives delivery of hyaluronic acid from Italian manufacturer Fidia

Interim report January – June 2021

Invitation to Conference Call regarding Promore Pharma’s Q2 Report 2021

The rights issue is registered and the trading in Paid Subscription Shares ceases

Outcome in Promore Pharma’s rights issue

Promore Pharma publishes prospectus

Promore Pharma informs about the last day of trading to receive subscription rights

Interim report January – March 2021

Report from an extra General Meeting of Promore Pharma AB held on 27 May 2021

Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021

Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna

Invitation to Conference Call regarding Promore Pharma’s Q1 Report 2021

Promore Pharma is granted a US patent regarding skin scarring

Notice of Extraordinary General Meeting in Promore Pharma AB (publ)

Promore Pharma AB intends to carry out a fully secured rights issue in order to implement the new strategy

Promore Pharma’s Annual Report 2020 and AGM related Documents Published

Promore Pharma signs agreement on production of hyaluronic acid with Italian manufacturer Fidia

NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)

Promore Pharma comments on media reports about ensereptide

Promore Pharma deregisters warrants

Promore Pharma updates its strategy and focuses on scar prevention

Year-end report 2020

Invitation to Presentation of Promore Pharma’s Year-end report for 2020

Promore Pharma changes Certified Adviser to Erik Penser Bank AB

Promore Pharma participates at “Aktiespararna’s Stora Aktiedagen”

Interim report January – September 2020

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2020

Clarification of outcome in the clinical trial HEAL LL-37

Promore Pharma announces positive results from Phase IIb study of ropocamptide in the treatment of venous leg ulcers

Nomination Committee Appointed for the Annual General Meeting 2021 in Promore Pharma

Promore Pharma AB (publ) Interim report January – June 2020

Invitation to Presentation of Promore Pharma’s Interim Report for the Second Quarter 2020

Promore Pharma is Granted a Patent for ropocamptide in the US

Promore Pharma Appoints Erik Magnusson as Chief Financial Officer

Report from the Annual General Meeting of Promore Pharma AB held on 26 May 2020

Promore Pharma AB (publ) Interim report January – March 2020

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2020

Promore Pharma’s Annual Report 2019 Published

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma´s CFO leaves the company in 2020

Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial

Promore Pharma AB (publ) Year-end report 2019

Invitation to Presentation of Promore Pharma’s Year-end report for 2019

Promore Pharma has finalized recruitment of patients in HEAL LL-37 early

Promore Pharma’s rights issue completed

Promore Pharma publishes supplementary prospectus in connection with the ongoing rights issue

Promore Pharma AB (publ) Interim report January – September 2019

Promore Pharma is granted a patent for PXL01 in the US

Promore Pharma publishes prospectus in connection with rights issue

Report from the Extraordinary Shareholders’ Meeting of Promore Pharma AB held on 22 October 2019

Promore Pharma engages ABG Sundal Collier as liquidity provider

Nomination Committee Appointed for the Annual General Meeting 2020 in Promore Pharma

Notice of Extraordinary Shareholders’ Meeting in Promore Pharma AB (publ)

Promore Pharma Rights issue – correction of date

Promore Pharma Promore Pharma carries out a rights issue of approximately SEK 75 million, underwritten up to 80 percent, and intends to publish its interim report early

Promore Pharma AB (publ) Interim report January – June 2019

Promore Pharma is granted a patent for LL-37 in Japan

Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2019

Promore Pharma has recruited half of the patients in HEAL LL-37

Report from the Annual General Meeting of Promore Pharma AB held on 21 May 2019

Promore Pharma AB (publ) Interim report January – March 2019

Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2019

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma AB (publ) Year-end report 2018

Invitation to Presentation of Promore Pharma’s Year-end report for 2018

Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study

Subscription price for Promore Pharma’s warrants TO1 determined

PharmaResearch Products Ltd use call option in Promore Pharma

Promore Pharma AB (publ) Interim report January – September 2018

Promore Pharma receives approval for Phase III study with PXL01 in India

Nomination Committee Appointed for the Annual General Meeting 2019 in Promore Pharma

Promore Pharma has had a successful meeting with the FDA regarding PXL01

Promore Pharma has enrolled first patient in HEAL LL-37 in Poland

Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland

Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring

Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland

Interim report January – June 2018

Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2018

Promore Pharma receives approval for Phase IIb trial with LL-37

Report from the Annual General Meeting of Promore Pharma AB held on 16 May 2018

Promore Pharma AB (publ) Interim report January – March 2018

Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2018

Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd

Promore Pharma 2017 Annual report published

Västra Hamnen Corporate Finance Initiates Coverage on Promore Pharma

Notice of Annual General Meeting in Promore Pharma AB (publ)

Two new smart-phone based imaging products have been adopted by Promore Pharma AB

Promore Pharma Regains Rights for PXL01 Manufacturing

Year-end report 2017

Promore Pharma is granted a patent for PXL01 in the US

Promore Pharma Adjusts Plans for PXL01 in North America

Interim report January – September 2017

Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060

Promore Pharma Signs Agreement with CRO PCG Clinical Services

Promore Pharma Completes Extensive European Collaboration Regarding DPK-060

Promore Pharma Signs Manufacturing Agreement with APL

Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days

Interim report January – June 2017

Promore Pharma starts trading on Nasdaq First North on 6 July 2017

Promore Pharma awaiting approval from Nasdaq First North in next week

New share issue in Promore Pharma raises 76 MSEK ahead of listing on Nasdaq First North

Promore Pharma Carries Out a Share Issue Prior to Listing on Nasdaq First North

Interim report January – March 2017

Promore Pharma AB files phase III clinical trial application in India

Promore Pharma AB elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO

Promore Pharma and Cellastra Inc. Announce Phase III Clinical Collaboration to Develop Therapeutic Peptide PXL01 for the US Market

Promore Pharma is Seeking an Office Manager in Stockholm

New Chief Financial Officer in Promore Pharma

Promore Pharma Announces a Strategic Collaboration with Technomark Life Sciences

Pergamum AB and Lipopeptide AB Change Name to Promore Pharma

Promore Pharma Obtains Positive Feedback in Dialogue with The Medical Products Agency of Sweden

Lipopeptide AB Announces a Strategic Collaboration with Pharmaresearch Products LTD

Pergamum AB Announces Ownership Restructuring

Pergamum Announces Final Data from Phase I/II Study in Patients with Chronic Leg Ulcers

Pergamum Reports Positive Follow-Up Data from a Phase II Clinical Trial of PXL01 for Prevention of Post-Surgical Adhesions

Pergamum Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd.